Abstract
In low- and middle-income countries, the mortality of HIV-associated tuberculous meningitis (TM) continues to be unacceptably high. In this observational study of 228 HIV-infected patients with TM, we compared the mortality during the first nine months of patients treated with standard antituberculosis therapy (sATT), intensified ATT (iATT), and iATT with streptomycin (iATT + STM). The iATT included levofloxacin, ethionamide, pyrazinamide, and double dosing of rifampicin and isoniazid and was given only during the hospital admission (median 7 days, interquartile range 6-9). No mortality differences were seen in patients receiving the sATT and the iATT. However, patients receiving the iATT + STM had significant lower mortality than those in the sATT group (hazard ratio [HR] 0.47, 95% confidence interval [CI] 0.24 to 0.93). After adjusting for other covariates, the mortality hazard of the iATT + STM versus the sATT remained statistically significant (adjusted HR 0.2, 95% CI 0.09 to 0.46). Other factors associated with mortality were previous ATT and low albumin concentrations. The mortality risk increased exponentially only with CD4+ lymphocyte concentrations below 100 cells/μL. In conclusion, the use of iATT resulted in a clinic...Continue Reading
References
Jan 1, 1991·Clinical Pharmacology and Therapeutics·S KaojarernS Krittiyanunt
Sep 1, 1993·The American Review of Respiratory Disease·G A EllardB W Allen
Feb 16, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·G ThwaitesJ Farrar
Jan 10, 2003·American Journal of Respiratory and Critical Care Medicine·Amina JindaniDenis A Mitchison
Apr 30, 1960·British Medical Journal·J LORBER
Jun 9, 2005·The Journal of Infectious Diseases·Guy E ThwaitesJeremy J Farrar
Jan 27, 2007·AIDS·Diego CecchiniMarta Ambroggi
Aug 17, 2010·Tuberculosis·P R Donald
Sep 9, 2010·The Lancet Infectious Diseases·Suzaan MaraisBen J Marais
Feb 4, 2011·Trials·Dorothee HeemskerkJeremy Farrar
Mar 23, 2011·PLoS Medicine·Edward C Jones-LópezRoy D Mugerwa
Dec 17, 2011·PloS One·M Estée TörökJeremy J Farrar
Apr 4, 2012·Antimicrobial Agents and Chemotherapy·Dau Quang ThoMaxine Caws
Sep 8, 2012·Future Microbiology·Flavia BrancusiDorothee Heemskerk
Oct 30, 2012·The Lancet Infectious Diseases·Rovina RuslamiReinout van Crevel
Jan 15, 2013·Interdisciplinary Perspectives on Infectious Diseases·Gerardo Alvarez-UriaManoranjan Midde
Aug 13, 2013·Interdisciplinary Perspectives on Infectious Diseases·Gerardo Alvarez-UriaPraveen Kumar Naik
Sep 3, 2013·Tuberculosis Research and Treatment·Gerardo Alvarez-UriaPraveen Kumar Naik
Jan 2, 2012·Infectious Disease Reports·Gerardo Alvarez-UriaPraveen Kumar Naik
Feb 6, 2015·American Journal of Respiratory and Critical Care Medicine·Martin J BoereeUNKNOWN PanACEA Consortium
Feb 24, 2015·International Journal of Antimicrobial Agents·Lindsey Te BrakeRob Aarnoutse